Viracta Therapeutics (Viracta Therapeutics) Forward Dividend Yield % : 0.00% (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Forward Dividend Yield %?

As of today (2024-06-07), the Forward Annual Dividend Yield of Viracta Therapeutics is 0.00%.

As of today (2024-06-07), the Trailing Annual Dividend Yield of Viracta Therapeutics is 0.00%.

VIRX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Forward Dividend Yield % only.

Viracta Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Viracta Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, Viracta Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's Forward Dividend Yield % falls into.

Viracta Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Viracta Therapeutics (NAS:VIRX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Viracta Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (Viracta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (NAS:VIRX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Executives

Mark Rothera	director, officer: President and CEO	C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Daniel R. Chevallard	officer: Chief Executive Officer	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Darrel P. Cohen	officer: Chief Medical Officer	C/O VIRACTA THERAPEUTICS, INC., 2533 S. COAST HWY 101, SUITE 210, CARDIFF CA 92007
Lisa Rojkjaer	officer: Chief Medical Officer	C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Ivor Royston	director, officer: CEO & President	4401 WILSHIRE BLVD., SUITE 200, LOS ANGELES CA 90010
Jane Chung	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Flavia Borellini	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Stephen Rubino	director	C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Gur Roshwalb	director, 10 percent owner	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael Huang	director	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Thomas E Darcy	director	C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121